Q3FY17 Results : Grindwell Norton Ltd.
Bhagyashree Vivarekar / 01 Feb 2017
Grinndwell Norton Ltd. reported healthy consolidated numbers on the back of sound revenue growth for the quarter ended December 31, 2016, today.The company's total sales for Q3FY17 at Rs 337.97 crore represent a 0.72 per cent sequential increase and 15.71 per cent YoY increase.
Grinndwell Norton Ltd. reported healthy consolidated numbers on the back of sound revenue growth for the quarter ended December 31, 2016, today.
The company's total sales for Q3FY17 at Rs 337.97 crore represent a 0.72 per cent sequential increase and 15.71 per cent YoY increase.
Its operating profit (EBIT) for the quarter was Rs 33.68 crore, while its EBIT margin was 9.97 per cent.
The company's PAT of Rs 27.7 crore represents a sequential QoQ decline of 6.07 per cent and a YoY increase of 13.06 per cent.
The company's stock opened for trading at Rs 317.5 on the BSE and rose 0.35 per cent to close at Rs 320.6.
Grindwell Norton(GNO) Ltd is Indian company engaged in the business of abrasives (bonded, coated, non-woven, superabrasives and thin wheels) and silicon carbide. The company also manufactures and markets high performance refractories and performance plastics products. The company's Project Engineering Group (PEG) has a portfolio of diverse projects and is a proven engineering resource for Saint-Gobain companies in India and internationally.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.